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Abstract: Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment 
of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. 
This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered 
in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential anti-
metabolite properties, and only partial cross-resistance with other alkylators. Used in combination with rituximab in vitro, bendamustine 
shows synergistic effects against various leukemia and lymphoma cell lines. In clinical studies, bendamustine plus rituximab is highly 
effective in patients with relapsed-refractory indolent lymphoma, inducing remissions in 90% or more and a median progression-free 
survival of 23–24 months. The optimal dosing and schedule of bendamustine administration is largely undecided and varies among 
studies. Results of ongoing trials and dose-finding studies will help to further help ascertain the optimal place of bendamustine in the 
management of indolent NHL.
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Introduction
Non-Hodgkin’s  lymphoma  (NHL)  belongs  to  a 
diverse group of hematologic malignancies originat-
ing in B or T lymphocytes. Approximately 85% of 
NHLs are of B-cell origin, with the remainder mostly 
of T-cell origin. Non-Hodgkin’s Lymphoma (NHL) is 
the second-fastest growing cancer in terms of mortal-
ity with an incidence rate that has nearly doubled in 
the last four decades with an annual increase of 4%, 
due to reasons that are not entirely clear. NHL is the 
seventh most common cancer in the United States, 
contributes to approximately 4% to 5% of all cancer 
cases in the United States, and causes approximately 
3%  of  all  cancer-related  deaths.1  Currently,  nearly 
500,000 people are living with the disease or are in 
remission. More than 65000 new cases of NHL are 
diagnosed in the United States each year and there are 
approximately  20000  NHL-related  deaths.1    Similar 
estimates for the year 2004 in the European Union 
(EU) indicate 62300 new cases of NHL and 31500 
deaths associated with the disease.2
With an incidence of two out of 100 000, Follicu-
lar Lymphoma (FL) is the most frequent lymphoma 
in the western world after diffuse large B-cell lym-
phoma  (DLBCL)  and  is  by  far  the  most  frequent 
indolent lymphoma,3 hence often used as a treatment 
model for all other indolent lymphomas. FL repre-
sents  a  heterogenous  group  of  lymphoproliferative 
neoplasms  that  contain  mainly  centrocytes  and  a 
variable component of centroblasts, the frequency of 
which yields the grade (1, 2 or 3, depending on the 
percentage of centroblasts). The disease follows an 
unpredictable clinical course with some patients have 
waxing and waning disease for five years or more 
without  the  need  for  therapy,  while  others  present 
with more aggressive, symptomatic disease and high 
tumour burden requiring immediate treatment.
Historically, the median overall survival (OS) for 
patients with FL was 8–10 years, but outcomes have 
improved, largely attributable to the incorporation of 
rituximab into treatment regimens.4,5 Management of 
FL has, therefore, been traditionally approached either 
by watch and wait or with single-agent treatments 
with the principle of offering a good quality of life for 
a prolonged time.6 The appearance of more aggres-
sive regimens including combination-chemotherapy, 
radio-immunotherapy,7,8  high-dose  chemotherapy 
with stem-cell rescue9 and the positive effect of the 
addition  of  rituximab  to  the  latter,10,11  have  driven 
many clinicians to abandon this minimalist strategy 
while trying to obtain a prolongation of survival or 
even cure by giving more rigorous regimen at diagno-
sis or as soon as treatment was necessary. The use of 
rituximab with upfront chemotherapy is now consid-
ered standard. While a watch-and-wait approach may 
still be considered in selected patients, the majority 
(81%) of FL patients in the US receive therapy.12 In 
addition, more successful frontline approaches have 
made assessment of newer agents as apart of initial 
therapy a more difficult and long-term process.
However, a cure of FL is still elusive. The survival 
curve  of  FL  patients  is  a  continuously  descending 
straight line never reaching a plateau. Patients invari-
ably become refractory to rituximab over time and 
require a succession of treatments. Demonstration of 
efficacy in this patient population is tricky. Preclini-
cal data suggests that the biologic basis of rituximab 
resistance may vary as a function of the prior thera-
pies received.13 In addition, the optimal chemotherapy 
backbone of rituximab remains unsettled. Data from 
the US Lymphocare Project indicates the most com-
monly used regimens in the US are R-CHOP [ritux-
imab,  cyclophosphamide,  doxorubicin,  vincristine, 
and  prednisone]  (55%),  R-CVP  [rituximab,  cyclo-
phosphamide,  vincristine,  and  prednisone]  (23%), 
rituximab-fludarabine-based (16%) and other (6%).12 
Randomized data has shown that, while fludarabine 
yields  higher  response  rates  compared  with  regi-
mens such as CVP and CHOP, it also causes higher 
toxicity, including increased bone marrow damage, 
myelosuppression and potential infection risk.14 The 
lack of randomized data to show improved progres-
sion-free survival (PFS) or overall survival (OS) with 
fludarabine, in light of this increased toxicity, prob-
ably explains the general preference in the USA for 
R-CHOP and R-CVP.
While  novel  anti-CD20  molecules  do  offer  the 
prospect  of  enhanced  activity  relative  to  rituximab, 
clinical data is not very compelling. Yttrium-90 ibri-
tumomab tiuxetan and iodine-131 tositumomab have 
confirmed activity in patients refractory to single-agent 
rituximab,15 but their use has been constrained by strict 
eligibility criteria and other factors. In consequence, 
nearly all patients with FL receive rituximab at   multiple Bendamustine for indolent non-Hodgkins lymphoma
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times over their treatment. It is, thus, imperative that 
we establish benchmarks of activity in this unique and 
growing patient population for which there are no pub-
lished trials evaluating other agents or regimens.
Bendamustine is one such agent that may offer 
answers  to  the  questions  raised  in  the  discussion 
so  far  and  forms  the  basis  of  the  present  review. 
  Bendamustine (Treanda; Cephalon, Inc., Frazer, Pa) 
was synthesized in 1963 by Ozegowski and Krebs 
at  the  Institute  for  Microbiology  and  Experimen-
tal Therapy in Jena, in what was then the   German 
Democratic  Republic  (East  Germany).16  It  was 
extensively  used,  but  not  systematically  studied 
until the 1990s. Bendamustine received its first mar-
keting approval in Germany, under the trade-name 
  Ribomustin    (Mundipharma  International  Corpora-
tion Limited), for use as a single-agent or in com-
bination chemotherapy regimens for indolent NHL, 
multiple myeloma (MM), and chronic lymphocytic 
leukemia (CLL).
Several well-designed and well-supervised stud-
ies in recent years have provided exciting results that 
has enthused great interest in the potential role of 
bendamustine for treatment of lymphoproliferative 
disorders. Clinical trials appear to also indicate some 
activity of bendamustine in breast cancer, small-cell 
lung cancer, and leiomyosarcomas. The agent was 
granted orphan drug status in 2007 and subsequently, 
approved by the FDA for the treatment of CLL on 
March 20, 2008.17 On October 31, 2008, the FDA 
approved  bendamustine  for  treating  patients  with 
indolent B-cell NHL whose disease has progressed 
during or within 6 months of treatment with ritux-
imab or a rituximab-containing regimen.18 It is cur-
rently indicated in Germany,   Singapore and Hong 
Kong, and has been recommended for approval in 
the EU, for the treatment of various haematologi-
cal   malignancies. A new drug application has also 
recently  been  filed  in  Japan  for  the  treatment  of 
refractory and relapsed low-grade NHL and mantle 
cell lymphoma (MCL).
The  following  review  provides  an  overview  of 
the pharmacological properties of bendamustine and 
attempts  to  assemble  and  assimilate  the  presently 
available clinical trial data for the practicing clini-
cian contemplating this chemotherapy option in the 
  management of indolent NHL.
Chemistry, Pharmacology  
and Pre-Clinical Data
Chemically, the bendamustine molecule is gamma- 
[1-methyl-5-bis(β-chloroethyl)-amino-benzimidazolyl-
2]-butyric  acid  hydrochloride.16  The  molecule  has 
three structural elements: a mechlorethamine (nitro-
gen mustard) group, a benzimidazole ring and a butyric 
acid side chain. The nitrogen mustard group is struc-
turally similar to cyclophosphamide and chlorambu-
cil and gives the drug its alkylating properties, while 
the  butyric  acid  group  confers  water  solubility.17,19 
The benzimidazole ring, which replaces the benzene 
ring in chlorambucil, is similar in configuration to 
some purine analogs such as 2 chlorodeoxyadenosine 
and represents a unique facet of the molecule. The 
intent of adding this structure to the nitrogen mustard 
was to include the antimetabolite properties shown 
for benzimidazole. While there has been speculation 
that bendamustine may have purine analog activity as 
well, no definite evidence has been published.
While other alkylating agents, such as chloram-
bucil, cyclophosphamide, and melphalan have very 
analogous mechanisms of action to each other, that 
of  bendamustine  appears  to  differ.20,21  The  DNA 
breaks  induced  by  bendamustine  are  more  exten-
sive  than  those  produced  by  cyclophosphamide  or 
carmustine and more durable than those associated 
with  melphalan,  cyclophosphamide,  or  carmustine. 
  Bendamustine may also be associated with a rela-
tively slower repair of DNA damage than with other 
alkylating agents. The removal of DNA double-strand 
breaks  induced  by  bendamustine  hydrochloride  in 
breast carcinoma cell lines is comparatively slow with 
the majority of DNA double-strand breaks still being 
detectable after 24 h.22 This widespread DNA damage 
delays timely DNA repair, culminating in inhibition 
of mitotic checkpoints.
Bendamustine has recently been shown to simul-
taneously  trigger  several  distinct  apoptotic  path-
ways and has been linked to a stronger activation 
of intrinsic apoptosis, as well as an alternative cell 
death pathway. This unique mechanism differs from 
other alkylating agents by activation of DNA-damage 
stress responses and apoptosis, inhibition of mitotic 
checkpoints and induction of mitotic catastrophe.20,23 
Bendamustine has been shown to down-regulate sev-
eral mitosis-related genes, including polo-like kinase Tageja
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1 ( PLK-1),  Aurora  Kinase  A,  and  cyclin  B1  and 
  activate the primary DNA-damage signalling kinases, 
ataxia telangiectasia mutated protein and checkpoint 
kinase  2,  leading  to  G2  arrest,  and  also  activate 
p53 mediated apoptosis. Evidence also suggests that 
bendamustine activates a base-excision DNA-repair 
pathway. While other alkylators induce an alkyltrans-
ferase mechanism of DNA repair, Bendamustine does 
not; drug resistance based on alkylguanyl transferase 
expression may, as a result, not affect the efficacy of 
bendamustine.
The regulation of apoptotic pathways by benda-
mustine has many unique facets as well.20 The DNA 
damage  caused  by  alkylating  agents  genes  Noxa 
(p53-induced proapoptotic Bcl-2 family   member) and 
p21(Cip1/Waf1/cyclin-dependent kinase inhibitor 1A; 
p53-induced  cell  division  kinase  inhibitor)  were 
induced to a numerically greater extent with benda-
mustine than with chlorambucil or phosphoramide.
Bendamustine also leads to a striking up-regulation 
of Ser,15 which is one of the key initial events known 
to  trigger  apoptosis  through  p53.  P53  levels  were 
increased to a numerically greater extent by benda-
mustine than by phosphoramide, and did not change 
at  all  following  exposure  to  chlorambucil.  Also, 
  Bendamustine was the only agent to cause an appre-
ciable increase in the protein expression of Bax in 
SU-DHL-1 cells leading to p53 mediated apoptosis.
In pre-clinical studies, bendamustine demonstrated 
exceptional activity in tumor cells resistant to other 
alkylating  agents.19  Earlier  studies  noted  that  the 
relative degree of resistance to bendamustine hydro-
chloride was lower in all cell lines compared with 
cyclophosphamide, melphalan and BCNU,22 suggest-
ing only incomplete cross-resistance. When investi-
gated in combination with other established cytotoxic 
drugs,  using  lymphoma  cell  lines  in  vitro  and  in 
ex vivo cells from patients with leukemic progression 
of lymphoma, bendamustine and cladribine exhibited 
in vitro synergy, while antagonism was observed with 
mitoxantrone and doxorubicin.24 Pre-clinical research 
also supported the use of bendamustine in conjunc-
tion with rituximab,25 fludarabine or gemcitabine.
Kanekal et al26 demonstrated synergism between 
bendamustine and rituximab using Daudi human lym-
phoma tumor xenografts in severe combined immu-
nodeficiency (SCID) mice. After 20 days of treatment 
with  bendamustine,  rituximab  or  a    combination 
of  both  treatments  (a  control  group  received  no 
  treatment), mice in treated groups had significantly 
(P-value not stated) smaller tumours than those in 
the  control  group,  and  the  combination  group  had 
significantly  (P  ,  0.02)  smaller  tumours  than  the 
rituximab group. This was further substantiated by a 
study showing that addition of rituximab reduces the 
dose of bendamustine required to induce apoptosis in 
CD20-positive  DOHH-2  and WSU-NHL  cell  lines 
and ex vivo B-cell CLL cells.27
Pharmacokinetics and Phase 1 Studies
After  an  intravenous  single-dose  administration 
(100 mg/m2) of bendamustine, peak plasma concen-
tration of the drug (Cmax) is typically reached near 
the end of the infusion period.17,18,29 The mean steady 
state volume of distribution is 25 L.17,30 The drug is 
94%–96% bound to serum plasma proteins, primar-
ily albumin, but only free bendamustine is pharma-
cologically active.17 Bendamustine is unlikely to be 
displaced  by  or  to  displace  highly  protein-bound 
drugs. In human blood, it appears to distribute freely 
in red blood cells, with a blood : plasma concentra-
tion ratio of 0.84–0.86 over a concentration range of 
10–100 mg/mL. The drug is eliminated mainly via 
feces (90%) and to a lesser extent in the urine.17
CYP1A2-catalyzed  N-dealkylation  and  gamma 
hydroxylation are the major routes for BM phase I 
metabolism producing two metabolites less or simi-
larly toxic than the parent compound.31   Nevertheless, 
active  metabolites  such  as  gamma-hydroxy-
  bendamustine  (M3)  and  N-desmethyl-bendamus-
tine  (M4)  occur  in  only  negligible  concentrations 
when compared to the parent component, and this 
implies  that  the  cytotoxic  activity  of  bendamus-
tine is mainly generated by the original compound. 
Nonmetabolized particles have been found to con-
stitute 45% of the excreted portion of the drug in 
urine.32 Phase II conjugation with glutathione may be 
another major route of bendamustine metabolism in   
humans.
Preliminary research shows that pharmacokinet-
ics of bendamustine are not affected by age or mild 
hepatic  or  renal  sufficiency.17  The  effects  of  more 
severe  hepatic  or  renal  impairment  have  not  been 
investigated However, our experience with this drug 
is limited, and hence, caution must still be used in 
patients with hepatic or renal insufficiency. The effect Bendamustine for indolent non-Hodgkins lymphoma
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of race on bendamustine pharmacokinetics has not yet 
been established; however, a study of 6 Japanese sub-
jects did indicate that their bendamustine exposure 
was  40%  higher  than  the  non-Japanese  subjects.17 
Older age and sex do not appear to affect the pharma-
cokinetics of bendamustine in patients with NHL.
Also,  the  drug-drug  interactions  involving 
bendamustine  have  not  been  formally  studied. 
CYP1A2 inhibitors or inducers may affect bendamus-
tine pharmacokinetics, as bendamustine is metabo-
lized via this pathway; caution is recommended. In 
an evaluation of a wide range of CYP isoenzymes 
using human hepatic microsomal preparations or pri-
mary cultures of human hepatocytes, bendamustine 
did  not  induce/inhibit  any  iso-enzymes,  including 
CYP1A2.17,30 Administration of bendamustine during 
organogenesis in rodents resulted in decreased body 
weights  and  increased  fetal  malformations.  benda-
mustine has been classified as a Pregnancy Category D 
medication.17 Therefore, women of childbearing age 
should avoid pregnancy with adequate birth control 
methods.
In wake of sub-optimal drug development strate-
gies in its formative years, the use of Bendamustine 
has been tried using a variety of doses and   schedules. 
Early studies used single doses of 150 mg/m2 ben-
damustine on days 1 and 2 of a 4-week treatment 
course.33 Using a day 1 and 8 of an every 3 weeks 
schedule34  produced  a  MTD  of  140  mg/m2,  with 
fatigue and dry mouth as DLTs. A high incidence of 
lymphocytopenia was also seen, but with no opportu-
nistic infections. The use of weekly   bendamustine35 
reported  a  MTD  of  80  mg/m2,  with  cholinergic 
events,  fatigue  and  fever  as  DLTs. Again  a  near 
absolute lymphocytopenia was noted (11 out of 12 
patients). Flow cytometric studies demonstrated that 
bendamustine had a deleterious effect on all lym-
phocyte subsets, but most prominently on B cells. 
The third phase I trial using a single dose of ben-
damustine  every  3  weeks28  determined  the  MTD 
at 280 mg/m2. Grade 4 thrombocytopenia, grade 3 
fatigue,  and  grade  2  cardiotoxicity  were  encoun-
tered, the latter considered dose limiting. The phar-
macokinetic evaluation revealed a mean elimination 
half-life of bendamustine in plasma of 49.1 min with 
the volume of distribution being 18.3 lm2 and the 
clearance 265 mlmin1 m2, with no evidence of dose-
dependency.
The most recent phase I study29 used a 30 min 
intravenous infusion of bendamustine for two con-
secutive  days  every  3  weeks.  Thrombocytopenia 
grade 4 was the DLT at 180 mg/m2 per day. Other 
important toxicities were long-lasting lymphocytope-
nia, observed from the first cycle onwards and present 
in every patient irrespective of the given dose, and 
some non-hematologic toxicity, that is, fatigue, loss 
of appetite, nausea and vomiting. The recommended 
dose for further phase II testing is 160 mg/m2 per 
day. The pharmacokinetic profile (PK) of bendamus-
tine produced virtually identical results, which when 
compared to previous results, suggest a lack of sched-
ule dependency. A recent phase 1 study from Japan 
used bendamustine 90 or 120 mg/m2 (dose escala-
tion)  administered  intravenously  over  60  min  on 
days 1 and 2 every 3 weeks for up to three cycles.36 
Nine patients (eight indolent B-NHL and one MCL) 
received per-protocol treatment, three at 90 mg/m2 
and  six  at  120  mg/m2.  No  dose-limiting  toxicities 
were  observed;  thus,  the  maximum-tolerated  dose 
was not reached.
Owen  et  al37  conducted  a  population  pharma-
cokinetic analysis of bendamustine in patients with 
indolent NHL treated with 120 mg/m2 day 1 and 2 
every  3  weeks.  Plasma  concentrations  declined 
in a triphasic manner, with a rapid biphasic phase 
(t1/2α = 17 minutes, t1/2β = 42 minutes) and a slow 
terminal  phase  (t1/2c  =  110  hours).  The  terminal 
phase  contributed  less  than  1%  of  the  total AUC, 
and therefore, the half-life of the β-phase was deter-
mined to be bendamustine’s mean half-life, which is 
  approximately 40 minutes.
Bendamustine Monotherapy
In a single institution trial from 2001,38 58 patients 
with relapsed low-grade NHL (CLL 27, centroblastic/-
cytic 22, centrocytic 6, immunocytic 3) were enrolled 
and treated with bendamustine 120 mg/m2 as a 1-h 
infusion on 2 consecutive days of 3-week cycle. The 
treatment  was  repeated  until  complete  remission 
(CR), partial remission (PR) or stable disease (SD) 
was confirmed on two consecutive cycles. A median 
of 6 cycles were given; 52 patients were evaluable 
for response and toxicity. The overall response rate 
was 73% (11% CR, 62% PR). SD was seen in 10% 
with progressive disease (PD) in 17% patients. The 
median duration of remission and survival was 16 and Tageja
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36 months, respectively. The regimen was   surprisingly 
well-tolerated and no treatment-related mortality was 
noted. Only 3 patients experienced grade 3 or 4 tox-
icity (grade 3 leukopenia). A subsequent European 
study39  enrolled  102  patients  with  relapsed  indo-
lent lymphomas (CLL 15, MM 25, immunocytic 46 
and others 16) and treated them with bendamustine, 
60 mg/m2, days 1–5 every 4–6 weeks. A median of 
4 cycles (1–11) were given; no TRM was seen. The 
ORR was 77% with SD 20% and PD in 4%.
These results stirred healthy interest in the US 
and consequently, a phase 2 multi-center study was 
designed to appraise the efficacy and toxicity of ben-
damustine  in  patients  with  B-cell    non-Hodgkin’s 
lymphoma  (NHL)  refractory  to  rituximab.40 
Patients  enrolled  on  this  study  were  defined  as 
  rituximab-refractory if they failed to respond or pro-
gressed within 6 months of previous treatment with 
  rituximab. Unlike the larger noncomparative study 
described  below,  patients  who  were  intolerant  of 
continued rituximab therapy were also included in 
this phase II study. 76 patients with predominantly 
stage  III/IV  indolent  (80%)  or  transformed  (20%) 
disease were treated using bendamustine 120 mg/m2 
intravenously on days 1 and 2 of each 21-day cycle; 
74 were assessable for response. Patients received 
a median of two (range, one to five) prior unique 
regimens;  twenty-four  (32%)  were  refractory  to 
chemotherapy. Grade 3 or 4 reversible hematologic 
toxicities  included  neutropenia  (54%),  thrombo-
cytopenia (25%), and anemia (12%). Patients with 
relative thrombocytopenia at baseline (inclusion cri-
teria allowed patients with platelet counts of at least 
100,000/mm3) were often incapable of tolerating the 
full  dose  of  bendamustine  and  dosage  reductions 
were requisite.   Non-  hematologic toxicities were com-
mon, but generally mild. An ORR of 77% (15% CR, 
19% unconfirmed CR, and 43% PR) was observed. 
Among patients with fludarabine-refractory disease 
(n = 8), the ORR was 62%. The median duration of 
response (DOR) was 6.7 months (95% CI, 5.1 to 
9.9 months); 36 percent of these responses exceeded 
1 year. The median DOR was only 2.3 months in the 
transformed population, but limiting the analysis to 
the patients who had indolent histology resulted in a 
median DOR of 9 months.
Durable responses were seen in a similarly desi-
gned multicentre phase II trial of 102 patients with 
  rituximab-refractory indolent and transformed NHL.41 
76%  patients  had  advanced-stage  disease  at  enrol-
ment; histologies included FL (n = 63), SLL (n = 21), 
lymphoplasmacytoid  lymphoma  (n  =  1),  and  MZL 
(n = 16). The ORR was 75% (a 14% CR, a 3% uncon-
firmed CR, and a 58% PR). Among alkylator-  refractory 
subjects (n = 30), the ORR was 60%. The median PFS 
for the overall study population was 9.3 months at a 
median follow-up of 11.8 months. Efficacy of benda-
mustine was comparable in different indolent histo-
logical subtypes; ORR was 74% among the 62 patients 
who had FL and 71% among the 21 patients who had 
SLL. These results highlighted the promising clinical 
activity of bendamustine in patients with rituximab-
refractory,  indolent  B-cell  lymphoma  and  formed 
the basis for approval by the United States Food and 
Drug Administration in   October 2008. Most recently, 
a   Japanese phase 2 study42 enrolled 58 patients with 
indolent B-NHL and 11 with MCL; using 120 mg/m2 on 
days 1–2 of a 21-day cycle for up to six cycles, benda-
mustine produced an ORR of 91%; 90% and 100% in 
patients with indolent B-NHL and MCL,   respectively), 
with a CR rate of 67% (95% CI, 54%–78%). After a 
median follow-up of 12.6 months, median PFS had 
not been reached. Estimated PFS rates at 1 year were 
70%  and  90%  among  indolent  B-NHL  and  MCL 
patients,  respectively.  Bendamustine  was  generally 
well tolerated. In general, the remission rates induced 
by bendamustine mono-therapy are high, but the dura-
tion of remission is rather short (Table 1) suggesting 
that bendamustine monotherapy may be inadequate 
for this patient sub-group.
Bendamustine in combination 
Chemotherapy
In  the  early  years,  studies  using  bendamustine  in 
combination chemotherapy regimens were crippled 
by  inconsistent  response  assessments.  The  combi-
nation  with  vincristine  and  prednisone  was  evalu-
ated in 4 small trials with a total of 157 patients.43–46 
The  ORR  ranged  from  66%–90%  (CR  22%–45%, 
PR  41%–52%).  Mitoxantrone  used  in  conjunction 
with bendamustine produced rewarding results, with 
an ORR of 59% (7% CR, 52% PR).47 The BMMP 
regimen  (bendamustine/mitoxantrone/methotrexate/ 
prednisone)  reported  an  ORR  of  48%  (13%CR, 
35%  PR)  in  23  patients.48 An  ORR  of  79%  (29% 
CR, 50% PR) was seen in 14 patients treated with Bendamustine for indolent non-Hodgkins lymphoma
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  bendamustine  was  combined  with  idarubicin  and 
dexamethsone.49  Another  small  study  comprising 
38 patients used bendamustine/etoposide and repor-
ted an ORR of 97% (67% CR, 30% PR).50
The Eastern German Study Group for Hematology 
and Oncology (OSHO) compared the efficacy and 
toxicity of bendamustine, vincristine and prednisone 
(BOP) with a standard regimen of cyclophosphamide, 
vincristine and prednisone (COP) in a phase 3 trial com-
prising patients with previously untreated advanced 
indolent non-Hodgkin’s lymphoma (NHL) and man-
tle cell lymphoma.51 No significant differences were 
seen in the ORR, DOR and overall survival, although 
BOP caused less toxicity. A clear survival advantage 
was, however, pragmatic in patients who responded 
(PR or CR) to BOP relative to those who responded to 
COP (5-year projected survival rate of 74% and 56%, 
respectively; P = 0.05). When the available data was 
sub-divided  based  on  tumour  histopathology,  BOP 
recipients with FL or LPL had a significantly superior 
5-year survival rate than those with mantle cell lym-
phoma (66% and 74% versus 43%; P = 0.03). Patients 
with MCL had an OS of 34 months, compared with 
76 months and 64 months, respectively, for those with 
FL or LPL. Another study by the OSHO group using 
bendamustine and   fludarabine52 reported an ORR of 
77%; 8 out of 15 responders relapsed after a median 
of 14 months.
Bendamustine in combination  
with Rituximab
In 1999, a small pilot study provided the preliminary 
evidence of the efficacy of bendamustine/ rituximab 
combination in patients with relapsed-refractory lym-
phoma. Weide and colleagues used a combination of 
bendamustine,  mitoxantrone  and  rituximab  (BMR) 
in alkylator resistant indolent B-cell   malignancies.53 
The dose of bendamustine was 90 mg/m2 on day 1–2, 
with  mitoxantrone  (M)  10  mg/m2  on  day  1  and 
  rituximab (R) 375 mg/m2 on day 8, 15,22 and 29. 
Bendamustine was repeated on day 36 for 3–5 more 
cycles every 28 days. Final results of this pilot study, 
published in 2002,54 reported an ORR of 96% (52/54) 
with CR 41% (22/54) and PR 55% (30/54). No TRM 
or  hospitalizations  were  reported.  Of  note,  46% 
patients received only one cycle of BMR, suggest-
ing outstanding potency.55 Treatment responses were 
durable, with majority of subjects in CR 9 years after 
the completion of treatment.
This promise culminated in a multi-center phase 2 
trial that firmly established the efficacy of BMR regi-
men in rituximab pre-treated, relapsed/refractory FL, 
MCL and other indolent lymphomas.56 Treatment con-
sisted of bendamustine 90 mg/m2 days 1 + 2, mitox-
antrone 10 mg/m2 day 1, rituximab 375 mg/m2 day 8 
and was repeated on day 29 for a total of four cycles. 
Overall  response  rate  (ORR)  was  89%  (CR  35%, 
PR 54%). ORR in R-chemo pre-treated patients was 
76% (38% CR, 38% PR). After a median observation 
time of 27 months,1–13 the estimated median progres-
sion free survival was 19 months. The 2 year overall 
  survival was 60% for patients with FL and MCL.
Analogous to this study, a multicenter trial evalu-
ated the progression-free survival, response rate and 
  toxicity  of  the  combination  of  bendamustine  and 
  rituximab (BR) in patients with mantle cell or low-
grade lymphomas.57 63 patients were accrued (FL 24, 
MCL 16, LPL [lymphoplasmacytic lymphoma] 17 and 
MZL [marginal zone lymphoma] 6).   Bendamustine 
was administered at a dose of 90 mg/m2 as a 30-minute 
infusion on days 1 and 2, combined with 375 mg/m2 
rituximab on day 1, for a maximum of four cycles 
every 4 weeks. All but four patients received all four 
cycles of treatment; no dose reductions were needed. 
Leukopenia  was  the  most  common  side  effect 
(16% grade 3–4 events); no evidence of cumulative 
myelosuppression was found. There was no TRM. 
None of the patients suffered from alopecia, a toxicity 
Table 1. Studies using bendamustine monotherapy in indolent NHL.
Study (reference) number ORR (%) CR (%) PR (%) DOR (months) PFS (months) OS (months)
Heider et al38 58 73 11 62 16 36
Bremer et al39 102 77 11 66 39 29
Kahl et al41 38 84 29 53 9.3 9.7
Friedberg et al40 76 77 15 43 6.7 7.1
Ohmachi et al42 69 91 39 53Tageja
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that is severe with other   alkylator- or anthracycline-
containing regimens, and of exacting importance, no 
organ toxicity was seen. The ORR in all 63 patients 
was 90% (CR 60%, PR 30%). The ORR in patients 
with  relapsed  MCL  was  75%  (n  =  12/16);  50% 
achieved CR. The responses were fairly durable, with 
median PFS for all patients being 24 months (range, 
5 to 44+ months) and 41 patients still in remission 
(at the time of publication). In an American study 
that followed, 66 patients were treated with the BR 
  regimen.58 The ORR was 92% (41% CR, 14% uCR, 
and  38%  PR).  The  median  DOR  and  PFS  were 
21 months and 23 months, respectively. Outcomes 
were similar for patients with both indolent and man-
tle cell histologies. Myelosuppression was the pri-
mary toxicity (grade 3 or 4 neutropenia, 36%; grade 3 
or 4   thrombocytopenia, 9%).
Taking a step further to see if this combination 
would benefit patients if used upfront, a multicenter 
  randomized phase-III study was initiated in October 
2003 to compare efficacy and safety of B-R versus 
CHOP plus rituximab (CHOP-R) as first-line ther-
apy for patients with follicular (FL), indolent and 
mantle  cell  lymphomas  (MCL).59  549  patients  in 
need of treatment were randomized to receive ritux-
imab 375 mg/m2 (day 1) plus either bendamustine 
90 mg/m2 (days 1+2) every 28 days or the standard 
CHOP  regimen  every  21  days  for  a  maximum  of 
6 cycles. 513 randomized patients were evaluable for 
the final analysis (B-R: n = 260; CHOP-R: n = 253). 
A median number of 6 cycles was given in both treat-
ment arms each. 82% of B-R and 86% of CHOP-R 
group received 6 cycles. While the ORR for patients 
treated with B-R was similar to the CHOP-R group 
(93,8% vs. 93,5%, respectively), the CR rate was 
significantly higher with 40,1% for B-R compared 
to 30,8% for CHOP-R. The median PFS, event-free 
survival (EFS) and time to next treatment (TTNT) 
were significantly longer after B-R compared to after 
CHOP-R. CHOP-R treatment was more frequently 
associated  with  serious  adverse  events  (SAE) 
(n = 49 in B-R vs. n = 74 in CHOP-R). Significant 
differences in hematologic toxicities were observed 
for neutropenia grade 3+4 (BR 10,7% vs. CHOP-R 
46,5%; P , 0.0001) and for leukocytopenia grade 
3+4 (BR 12,1% vs. CHOP-R 38,2%; P , 0.0001). 
G-CSF was more often used in CHOP-R treated pts 
(20,0% of all cycles) than it was used in the B-R 
group (4,0%) (P , 0.0001).
When  combined  with  fludarabine  and  ritux-
imab  (BFR)  in  the  treatment  of  relapsed  indolent 
lymphomas,60  the  regimen,  given  over  4  cycles, 
appeared  to  be  effective  with  an  ORR  of  76% 
(28% CR, 48% PR). Unfortunately, the study could 
not be continued due to a significant hematotoxicity 
and a high rate of serious infections.
Results  of  the  above-mentioned  studies  clearly 
demonstrate the efficacy of combined bendamustine 
and  rituximab  for  patients  with  relapsed  indolent 
and mantle cell NHL (Table 2). BR elicits responses 
that are durable, with a low incidence of severe and 
life-threatening  events.  Also,  excellent  activity  is 
seen against low-grade lymphomas across multiple 
  histological subtypes.
Table 2. Selected studies using bendamustine combination therapies in NHL.
Study (reference) Bendamustine plus no. ORR (%) CR (%) PR (%)
Ruffert et al43 vincristine + prednisone 31 90 38 52
Blumenstengel et al44 vincristine + prednisone 22 86 45 41
Herold et al45 vincristine + prednisone 82 66 22 44
Kath et al46 vincristine + prednisone 22 86 45 41
Heck et al47 Mitoxantrone 29 59 7 52
Kahl et al48 Mitoxantrone + MTX + prednisone 23 48 13 35
König et al49 Dexamethasone + idarubicine 14 79 29 50
Ruffert50 etoposide 38 97 67 30
Kirchner et al60 Fludarabine + rituximab 25 76 28 48
weide et al55 Mitoxantrone + rituximab 54 96 41 55
Königsmann et al52 Fludarabine 29 77 45 32
Rummel et al57 Rituximab 63 90 60 30
Robinson et al58 Rituximab 54 84 21 63
weide et al56 Mitoxantrone + rituximab 57 89 35 54Bendamustine for indolent non-Hodgkins lymphoma
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Recent Updates
In a freshly published single-center phase 2 trial,61 
the combination of weekly bendamustine and bort-
ezomib was evaluated in patients with relapsed or 
refractory Indolent NHL or B-CLL. 12 patients were 
enrolled  (MCL  5,  FL  4,  CLL  2,  and  WM  1). All 
patients had received a median of three prior treat-
ment lines (range 1–8). On Days 1, 8, 15, and 22 of 
a 35-day cycle patients received intravenous bolus 
bortezomib 1.6 mg/m2 for a maximum of three cycles. 
  Bendamustine was administered as 30-minute intrave-
nous infusion on Days 1, 8, and 15 before bortezomib. 
Dose escalation was started at 60 mg/m2 bendamus-
tine (level 0) with 80 mg/m2 as the first escalation step 
(level 1). Four patients were treated per dose level. 
Without dose-limiting toxicity (DLT), the bendamus-
tine dosage was escalated. The four patients enter-
ing dose level 0 showed no DLT. In three out of five 
patients on level 1, DLT was eventually observed, 
thus defining MTD. Adverse events with an overall 
incidence of $20% were diarrhea, nausea, vomiting, 
anemia, leukopenia, neutropenia, thrombocytopenia, 
and  fatigue.  The  combination  worked  particularly 
well in MCL; all patients responded. Results, how-
ever, were not that encouraging in FL; all cases of PD 
were observed in FL.
Friedberg and colleagues62 recently published the 
results of a phase 2 study that included patients with 
relapsed or refractory indolent and mantle cell lym-
phoma and adequate organ function. Therapy included 
bendamustine  90  mg/m2  days  1  and  4;  rituximab 
375 mg/m2 day 1, and bortezomib 1.3 mg/m2 days 1, 4, 
8, 11. Six 28-day cycles were planned. Thirty patients 
(7 with mantle cell lymphoma) were treated. Eight 
patients experienced serious adverse events, including 
one event of grade 5 sepsis.   Non-hematologic adverse 
events were generally grade 1 or grade 2 and included 
nausea  (50%),  neuropathy  (47%),  fatigue  (47%), 
constipation (40%), and fever (40%). Of 29 patients 
evaluable, 24 (83%) achieved an objective response 
(including 15 with complete response). With median 
follow-up of 24 months, 2-year   progression-free sur-
vival is 47% (95%   confidence interval, 25%–69%).
Addressing  a  similar  combination,  the  phase  1 
portion  of  the VERTICAL  trial  reported  at ASCO 
identified 90 mg/m2 on days 1 and 2 as the dose of 
bendamustine for phase 2 studies.63 At ASH 2009, 
Fowler and colleagues presented phase 2 data64 on 
the VBR combination in 49 patients with relapsed 
and refractory FL. The 5 cycles of VBR combina-
tion were delivered at 5-week intervals as follows: 
bendamustine 90 mg/m2 on days 1 and 2; rituximab 
375 mg/m2 on day 1, 8, 15, and 22 of the first cycle 
and day 1 of each subsequent cycle; and bortezomib 
1.6 mg/m2 weekly for 4 weeks. The ORR was 80% 
with 47% CR.
Sequential  use  of  chemo-immunotherapy  with 
bendamustine  followed  by  radio-immunotherapy 
has also been reported.65 10 patients with relapsed-
  refractory  indolent  lymphoma  and  MCL  were 
treated  using  3  cycles  of  BMR  followed  by  90Y-
  ibritumomab  tiuxetan  (Zevalin  TM).  The  ORR   
was 90% (CR 60%, PR 30%, PD 10%). 5 out of 6 
patients in CR achieved a durable response. Revers-
ible grade 3–4   hematotoxicity after Zevalin TM was 
the only major adverse event.
A phase 1 Trial of Bendamustine, Lenalidomide 
and Rituximab in CLL and NHL (Phase I BLR) is pres-
ently enrolling patients at the Georgetown University 
Hospital/Lombardi  Cancer  Center,  USA66  with  the 
intention of evaluating overall safety profile, plasma 
pharmacokinetics and preliminary antitumor activity. 
A similar study across the Atlantic67 will investigate 
the use of BLR regimen in in patients with relapsed or 
refractory aggressive B-cell lymphoma who are not 
eligible for High Dose Chemotherapy (HDC).
Researchers  at  MD  Andersen  Cancer  Center 
(MDACC) are evaluating the safety and efficacy of 
Fludarabine,  Bendamustine  and  Rituximab  condi-
tioning in an open label trial68 with the primary aim of 
reporting the MTD of Bendamustine when given with 
a stem cell transplant and chemotherapy (fludarabine 
and  rituximab).  Another  non-randomized  study  at 
MDACC is making use of the Bendamustine, Mitox-
antrone,  and  Rituximab  (BMR)  combination  for 
patients with previously untreated FL.69 This study, 
in addition to confirming the results of European tri-
als,  will  aim  to  determine  the  correlation  between 
molecular complete response and response to therapy 
and examine the immediate and prolonged effects of 
BMR on immune effector cell number and function.
Challenging the current standard of care for patients 
with  FL,  an  open-label,  randomized,  multi-center 
study of the BR regimen compared with R-CVP or 
R-CHOP in the first-fine treatment of patients with 
advanced Indolent NHL or MCL (The Bright Study) Tageja
154  Clinical Medicine Insights: Oncology 2011:5
is  presently  recruiting  participants.70  With  the  pri-
mary aim of comparing the CR rates, the study will 
enrol 296 participants and report preliminary results 
in 2011.
Further studies may use bendamustine in combi-
nation with immuno-modulators such as thalidomide 
and lenalidomide or newer anti-B cell antibodies, such 
as  Ofatutumab,  a  humanized  anti-CD20  molecule 
recently approved for treatment of refractory CLL.
Current Place of Bendamustine  
in the Treatment of Indolent 
Lymphoma
The approved dosage regimen of bendamustine for 
indolent NHL in the US is 120 mg/m2 infused intrave-
nously over 60 minutes on days 1 and 2 of each 21-day 
cycle for up to eight cycles17,18 with some patients 
requiring a dose-reduction to 90 or 60 mg/m2. How-
ever, most experts recommend a dose of 90 mg/m2 on 
days 1 and 2 when bendamustine is used in combina-
tion with rituximab, based on data in relapsed setting; 
however, this regimen is not yet FDA approved.71,72 
Outside of a clinical trial, bendamustine should not 
be combined empirically with any other myelosup-
pressive chemotherapy agent. As for the duration of 
treatment, a panel of international experts recently 
recommended that six cycles is likely to be adequate 
for previously untreated patients while for relapsed/
refractory cases, 4–6 cycles are be intended based on 
tolerance and co-morbidities.72 Patients who experi-
ence grade 3 or worse myelosuppression may be con-
sidered for myeloid growth factor support with future 
drug exposure; dose delay and/or reduction may be 
unavoidable in some situations.
Conclusions
The future is full of exciting possibilities for those 
seeking a cure for indolent lymphomas. Multiple small 
molecules and novel compounds have shown prom-
ising activity in broad-based pre-clinical and clinical 
studies in B-cell malignancies. However, the challenge 
lies in determining which patient subsets may gain the 
most from these newer agents and which combinations 
may be of most benefit for patients with FL.
The promise of Bendamustine lies in its efficacy, 
favorable tolerability profile, ease of administration, 
and  lack  of  cross-resistance  with  commonly  used 
chemotherapeutic agents. However, many questions 
remain unanswered. The precise mechanism of action 
and  of  resistance  is  largely  debatable;  the  optimal 
dose and schedule is not firmly established yet. BM 
has  not  been  evaluated  in  patients  with  moderate- 
severe liver or renal dysfunction; hence, more precise 
dosing strategies are required. The influence of prior 
bendamustine therapy on stem cell mobilization and 
harvest is principally unknown. Also, the relationship 
between bendamustine and secondary myelodysplas-
tic syndromes needs to be carefully studied.
Ongoing and future studies will help to better 
define the place of bendamustine in the manage-
ment  of  indolent  NHL.  Bendamustine  may  be  a 
very  reasonable  substitute  to  R-CHOP  in  elderly 
patients  with  multiple  co-morbidities,  including 
cardiac dysfunction. It will be of interest to look 
out for the results of studies evaluating the use of 
bendamustine in untreated patients, as the under-
lying disease may be somewhat more uniform in 
its characteristics and the variables of prior therapy 
can be eliminated.
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